The power of precision.
For every cancer patient.
Today.

Latest news
2CUREX APPOINTS OLE THASTRUP AS NEW CEO
Read more

Press releases & news

  • 2CUREX APPOINTS OLE THASTRUP AS NEW CEO

    Read more
  • Correction: 2CUREX AB ABORTS DELISTING AND ANNOUNCES DIRECTED SHARE ISSUE TO A PRIVATE INVESTMENT COMPANY AND SALE OF THE SUBSIDIARY 2CUREX A/S

    Read more
  • 2CUREX AB ABORTS DELISTING AND ANNOUNCES DIRECTED SHARE ISSUE TO A PRIVATE INVESTMENT COMPANY AND SALE OF THE SUBSIDIARY 2CUREX A/S

    Read more
  • NOTICE OF ANNUAL GENERAL MEETING OF 2CUREX AB (PUBL)

    Read more
All press realeases & news

Latest report

Latest presentation

  • 2CUREX PRESENTS AT REDEYE FIGHT CANCER

Calendar & upcoming events

All events

CEO Blog

In this latest blog, Fernando Andreu talks about the exciting expansion of the IndiTreat® product family to include a functional drug sensitivity test for pancreatic cancer in the near future.

Subscribe to our newsletter above.

More

Information for Oncologists and Pathologists

Know more when it matters most:
With our IndiTreat® tests you can finally obtain personalised information, even on the classic compounds for the main chemotherapy backbone for your stage IV mCRC patients.

More

Information for Patients

You’ve been diagnosed with colorectal cancer, and it is in stage IV. There are rational treatment choices to be made. Which therapy is more likely to impact the tumor? Ask your doctor about IndiTreat®.

More